Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Huiyun Ni

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|August 25, 2015
Low expression of miRNA-224 predicts poor clinical outcome in diffuse large B-cell lymphoma treated with R-CHOPHuiyun Ni, Xinfeng Wang, Hong Liu, et al.
Oncology Letters|February 20, 2016
MicroRNAs in diffuse large B-cell lymphomaHuiyun Ni, Rong Tong, Linqing Zou, et al.
Oncotargets and Therapy|July 7, 2016
Expression of CD40 is a positive prognostic factor of diffuse large B-cell lymphoma treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)Guoqi Song, Huiyun Ni, Linqing Zou, et al.
Current Cancer Drug Targets|August 23, 2014
Deregulated expression of miR-224 and its target gene: CD59 predicts outcome of diffuse large B-cell lymphoma patients treated with R-CHOPGuoqi Song, Guorong Song, Huiyun Ni, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|August 25, 2015
Low expression of miRNA-224 predicts poor clinical outcome in diffuse large B-cell lymphoma treated with R-CHOPHuiyun Ni, Xinfeng Wang, Hong Liu, et al.
Oncology Letters|February 20, 2016
MicroRNAs in diffuse large B-cell lymphomaHuiyun Ni, Rong Tong, Linqing Zou, et al.
Oncotargets and Therapy|July 7, 2016
Expression of CD40 is a positive prognostic factor of diffuse large B-cell lymphoma treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)Guoqi Song, Huiyun Ni, Linqing Zou, et al.
Current Cancer Drug Targets|August 23, 2014
Deregulated expression of miR-224 and its target gene: CD59 predicts outcome of diffuse large B-cell lymphoma patients treated with R-CHOPGuoqi Song, Guorong Song, Huiyun Ni, et al.
Pageof 1